drugset / Trial / NCT05027776
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3
Recruiting
1348 enrolled
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
Timeline
- Start
- 2021-09-15
- Primary completion
- 2023-11-22
- Completion
- 2026-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Measles mumps rubella (MMR) | Unknown | — | Intramuscular |